Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (281-290 of 1,124) with videos related to

Pageof 113
Sort By:
Molecular Cancer Therapeutics|December 30, 2021
Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic InstabilitySophie Gilbert, Benjamin Péant, Nicolas Malaquin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 30, 2021
Canadian Urological Association best practice report: Bone health in prostate cancerLuke T Lavallée, Ryan McLarty, Christopher Tran, et al.
Cancer Investigation|November 22, 2002
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronateAllan Lipton, E Small, Fred Saad, et al.
European Urology|August 31, 2014
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trialFred Saad, Johann de Bono, Neal Shore, et al.
The Canadian Journal of Urology|May 5, 2006
Prostate cancer nomograms are superior to neural networksPierre I Karakiewicz, Felix K-H Chun, Alberto Briganti, et al.
The Oncologist|April 24, 2012
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administrationAlfredo Berruti, Richard Cook, Fred Saad, et al.
European Urology|July 9, 2015
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic OptionsBenjamin A Gartrell, Robert Coleman, Eleni Efstathiou, et al.
European Urology|June 21, 2025
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS TrialMarc-Oliver Grimm, Matthew Smith, Maha Hussain, et al.
Cancer|September 12, 2008
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancerJoel B Nelson, William Love, Joseph L Chin, et al.
Cancer Medicine|December 5, 2024
Meeting Aerobic Physical Activity Guidelines and Associations With Physical Fitness in Men With Metastatic Prostate Cancer: Baseline Results of the Multicentre INTERVAL-GAP4 TrialLisa Umlauff, Stacey A Kenfield, Robert U Newton, et al.
Pageof 113

Showing results (281-290 of 1,124) with videos related to

Sort By:
Pageof 113
Molecular Cancer Therapeutics|December 30, 2021
Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic InstabilitySophie Gilbert, Benjamin Péant, Nicolas Malaquin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 30, 2021
Canadian Urological Association best practice report: Bone health in prostate cancerLuke T Lavallée, Ryan McLarty, Christopher Tran, et al.
Cancer Investigation|November 22, 2002
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronateAllan Lipton, E Small, Fred Saad, et al.
European Urology|August 31, 2014
Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trialFred Saad, Johann de Bono, Neal Shore, et al.
The Canadian Journal of Urology|May 5, 2006
Prostate cancer nomograms are superior to neural networksPierre I Karakiewicz, Felix K-H Chun, Alberto Briganti, et al.
The Oncologist|April 24, 2012
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administrationAlfredo Berruti, Richard Cook, Fred Saad, et al.
European Urology|July 9, 2015
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic OptionsBenjamin A Gartrell, Robert Coleman, Eleni Efstathiou, et al.
European Urology|June 21, 2025
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS TrialMarc-Oliver Grimm, Matthew Smith, Maha Hussain, et al.
Cancer|September 12, 2008
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancerJoel B Nelson, William Love, Joseph L Chin, et al.
Cancer Medicine|December 5, 2024
Meeting Aerobic Physical Activity Guidelines and Associations With Physical Fitness in Men With Metastatic Prostate Cancer: Baseline Results of the Multicentre INTERVAL-GAP4 TrialLisa Umlauff, Stacey A Kenfield, Robert U Newton, et al.
Pageof 113